WO2007141413A1 - Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie benigne de la prostate - Google Patents
Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie benigne de la prostate Download PDFInfo
- Publication number
- WO2007141413A1 WO2007141413A1 PCT/FR2007/000913 FR2007000913W WO2007141413A1 WO 2007141413 A1 WO2007141413 A1 WO 2007141413A1 FR 2007000913 W FR2007000913 W FR 2007000913W WO 2007141413 A1 WO2007141413 A1 WO 2007141413A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor antagonist
- cannabinoid
- treatment
- prevention
- benign prostatic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Definitions
- the present invention relates to the use of a cannabinoid CB1 receptor antagonist for the preparation of medicaments useful for the prevention and treatment of benign prostatic hypertrophy.
- the present invention relates to the use of a CB1 receptor antagonist to cannabinoids derived from pyrazole.
- a pyrazole-derived cannabinoid CB1 receptor antagonist means a compound selected from N-piperidino-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4-methylpyrazole-3 carboxamide whose international nonproprietary name is rimonabant, described in European Patent EP 656 354 and N-piperidino-5- (4-bromophenyl) -1- (2,4-dichlorophenyl) -4-ethylpyrazole-3-carboxamide, whose international nonproprietary name is surinabant, described in European Patent EP 1 150 961.
- Benign prostatic hypertrophy is a condition that is anatomically defined by an increase in the size of the prostate not due to cancer and histologically by fibromuscular and glandular hyperplasia.
- BPH is a fairly common condition and can occur in men over 40 years of age.
- the increase in prostate size may induce partial or complete obstruction of the urethra, which results in a decrease in the flow of seminal fluid and urine.
- cannabinoid receptor modulators for treating prostate cancers is described in many patent applications (for example: WO 2001/087297, WO 2003/086288, WO 2005/067917).
- results from the literature (Sarfaraz et al., Cancer Res., 2005, 65 (5), 1635-1641) show the effects of WIN-55,212-2, a mixed CB1 / CB2 agonist, on the proliferation and aptose cancerous prostate cells.
- a cannabinoid CB 1 receptor antagonist compound especially a cannabinoid receptor antagonist derived from pyrazole, selected from rimonabant and N-piperidino-5- (4-bromophenyl) -1- (2,4-dichlorophenyl) -4-ethylpyrazole-3-carboxamide, may be used for the preparation of medicaments useful for prevent and treat benign prostatic hypertrophy.
- compositions according to the present invention contain an effective dose of an antagonist compound j CB cannabinoid receptors, in particular an antagonist compound of the cannabinoid receptors derived from pyrazole, chosen from rimonabant and surinabant, and at least one excipient
- Said excipients are chosen according to the pharmaceutical form and the desired mode of administration, from the usual excipients which are known to those skilled in the art.
- the active ingredient may be administered in unit dosage form.
- in admixture with conventional pharmaceutical excipients to animals and humans for the prevention or treatment of the above disorders or diseases.
- Suitable unit dosage forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, oral, intratracheal, intraocular, intranasal forms of administration. by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants.
- the compounds according to the invention can be used in creams, gels, ointments or lotions.
- Forms for oral administration such as capsules or tablets are preferred.
- capsules or tablets containing rimonabant are preferred at a dose of between 5 and 50 mg, more particularly at doses of 5.10 and 20 mg.
- a cannabinoid receptor antagonist derived from pyrazole, chosen from rimonabant and surinabant
- another active ingredient that is useful in the treatment of BPH, for example a alpha blocker such as alfuzosin, tamsulosin, tetrazosin, doxazosin, prazosin or indoramine or an inhibitor of 5 alpha reductase such as fasterid or dutasteride.
- the subject of the present invention is the use of a pharmaceutical composition containing, in combination, rimonabant and palfuzosin, which is useful for the prevention and treatment of benign prostatic hypertrophy.
- the invention also relates to the use of a composition containing in combination surinabant and alfuzosin, useful for the prevention and treatment of benign prostatic hypertrophy.
- the pyrazole-derived cannabinoid receptor antagonist selected from rimonabant and surinabant and the other associated active ingredient may be administered simultaneously, separately or spread over time.
- disparate use is meant the administration, at the same time, of the two compounds of the composition according to the invention, each comprised in a separate pharmaceutical form.
- extended use over time is understood to mean the sequential administration of the first compound of the composition according to the invention, included in a pharmaceutical form, then, of the second compound of the composition according to the invention, included in a form pharmaceutical industry.
- the lapse of time elapsed between the administration of the first compound of the composition according to the invention and the administration of the second compound of the same composition according to the invention does not exceed usually not 24 hours, it may be higher if either compound is presented in a pharmaceutical formulation allowing, for example, a weekly administration.
- the pharmaceutical forms comprising either only one of the constituent compounds of the composition according to the invention or the combination of the two compounds, or, where appropriate, of three compounds, which can be used in the various types of uses described above. above, may for example be suitable for oral, nasal, parenteral or transdermal administration.
- two different dosage forms may be for the same route of administration or a different route of administration (oral and transdermal). or oral and nasal or parenteral and transdermal etc).
- EXAMPLE 1 Treatment of Testosterone-Induced BPH in Rats Male rats are implanted by catheters and receive 18.75 mg subcutaneously per testosterone rat at D-4. From day 0 to day D21, they receive daily rimonabant at a dose of 10 mg / kg or 30 mg / kg bone.
- Pretreatment with testosterone increased the weight and volume of the total prostate and ventral prostate of rats by approximately 35%.
- ventral prostate weight 87% 95% Decreased ventral prostate volume 88% 100%
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07788825A EP2037920A1 (fr) | 2006-06-07 | 2007-06-01 | Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie benigne de la prostate |
JP2009513726A JP2009539814A (ja) | 2006-06-07 | 2007-06-01 | 良性前立腺肥大症の予防および治療に有用な薬物を調製するためのカンナビノイドcb1受容体拮抗剤の使用 |
BRPI0711739-6A BRPI0711739A2 (pt) | 2006-06-07 | 2007-06-01 | utilização de um antagonista dos receptores cb1 aos canabinóides para o preparo de medicamentos úteis para a prevenção e o tratamento de hipertrofia benigna da próstata |
MX2008015474A MX2008015474A (es) | 2006-06-07 | 2007-06-01 | Utilizacion de un antagonista de los receptores cb1 de los cannabinoides para la preparacion de medicamentos utiles para la prevencion y el tratamiento de la hipertrofia benigna de prostata. |
AU2007255265A AU2007255265A1 (en) | 2006-06-07 | 2007-06-01 | Use of a cannabinoid CB1 receptor antagonist for preparation of drugs useful for the prevention and treatment of benign prostatic hypertrophy |
EA200870507A EA200870507A1 (ru) | 2006-06-07 | 2007-06-01 | Применение антагониста каннабиоидных рецепторов св1 для получения лекарственных средств, подходящих для лечения и профилактики доброкачественной гипертрофии предстательной железы |
CA002648645A CA2648645A1 (fr) | 2006-06-07 | 2007-06-01 | Use of a cannabinoid cb1 receptor antagonist for preparation of drugs useful for the prevention and treatment of benign prostatic hypertrophy |
NO20084293A NO20084293L (no) | 2006-06-07 | 2008-10-14 | Anvendelse av kannabinoid CB1 reseptorantagonist for fremstilling av legemidler nyttige for forebygging og behandling av godartet prostatisk hypertropi |
IL195079A IL195079A0 (en) | 2006-06-07 | 2008-11-03 | Use of a cannabinoid cb1 receptor antagonist for preparation of drugs useful for the prevention and treatment of benign prostatic hypertrophy |
US12/327,298 US20090124643A1 (en) | 2006-06-07 | 2008-12-03 | Use of a Cannabinoid CB1 Receptor Antagonist for Preparation of Drugs Useful for the Prevention and Treatment of Benign Prostatic Hypertrophy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0605074A FR2902008A1 (fr) | 2006-06-07 | 2006-06-07 | Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie begnine de la prostate |
FR0605074 | 2006-06-07 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/327,298 Continuation US20090124643A1 (en) | 2006-06-07 | 2008-12-03 | Use of a Cannabinoid CB1 Receptor Antagonist for Preparation of Drugs Useful for the Prevention and Treatment of Benign Prostatic Hypertrophy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007141413A1 true WO2007141413A1 (fr) | 2007-12-13 |
Family
ID=37773101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2007/000913 WO2007141413A1 (fr) | 2006-06-07 | 2007-06-01 | Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie benigne de la prostate |
Country Status (19)
Country | Link |
---|---|
US (1) | US20090124643A1 (fr) |
EP (1) | EP2037920A1 (fr) |
JP (1) | JP2009539814A (fr) |
KR (1) | KR20090016576A (fr) |
CN (1) | CN101460169A (fr) |
AR (1) | AR061236A1 (fr) |
AU (1) | AU2007255265A1 (fr) |
BR (1) | BRPI0711739A2 (fr) |
CA (1) | CA2648645A1 (fr) |
CL (1) | CL2007001632A1 (fr) |
EA (1) | EA200870507A1 (fr) |
FR (1) | FR2902008A1 (fr) |
IL (1) | IL195079A0 (fr) |
MA (1) | MA30850B1 (fr) |
MX (1) | MX2008015474A (fr) |
NO (1) | NO20084293L (fr) |
TW (1) | TW200812583A (fr) |
UY (1) | UY30400A1 (fr) |
WO (1) | WO2007141413A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010079241A1 (fr) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0656354A1 (fr) * | 1993-12-02 | 1995-06-07 | Sanofi | N-pipéridino-3-pyrazolecarboxamide substitué |
EP1150961B1 (fr) * | 1999-02-01 | 2003-10-22 | Sanofi-Synthelabo | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006039334A1 (fr) * | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinaisons d'azetidinones substituees et d'antagonistes cb1 |
-
2006
- 2006-06-07 FR FR0605074A patent/FR2902008A1/fr not_active Withdrawn
-
2007
- 2007-06-01 KR KR1020087029775A patent/KR20090016576A/ko not_active Application Discontinuation
- 2007-06-01 CA CA002648645A patent/CA2648645A1/fr not_active Abandoned
- 2007-06-01 JP JP2009513726A patent/JP2009539814A/ja not_active Withdrawn
- 2007-06-01 CN CNA2007800209782A patent/CN101460169A/zh active Pending
- 2007-06-01 EP EP07788825A patent/EP2037920A1/fr not_active Withdrawn
- 2007-06-01 AU AU2007255265A patent/AU2007255265A1/en not_active Abandoned
- 2007-06-01 EA EA200870507A patent/EA200870507A1/ru unknown
- 2007-06-01 MX MX2008015474A patent/MX2008015474A/es not_active Application Discontinuation
- 2007-06-01 WO PCT/FR2007/000913 patent/WO2007141413A1/fr active Application Filing
- 2007-06-01 BR BRPI0711739-6A patent/BRPI0711739A2/pt not_active IP Right Cessation
- 2007-06-05 TW TW096120153A patent/TW200812583A/zh unknown
- 2007-06-06 CL CL2007001632A patent/CL2007001632A1/es unknown
- 2007-06-06 AR ARP070102421A patent/AR061236A1/es unknown
- 2007-06-07 UY UY30400A patent/UY30400A1/es not_active Application Discontinuation
-
2008
- 2008-10-14 NO NO20084293A patent/NO20084293L/no not_active Application Discontinuation
- 2008-11-03 IL IL195079A patent/IL195079A0/en unknown
- 2008-12-03 US US12/327,298 patent/US20090124643A1/en not_active Abandoned
- 2008-12-05 MA MA31455A patent/MA30850B1/fr unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0656354A1 (fr) * | 1993-12-02 | 1995-06-07 | Sanofi | N-pipéridino-3-pyrazolecarboxamide substitué |
EP1150961B1 (fr) * | 1999-02-01 | 2003-10-22 | Sanofi-Synthelabo | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
Non-Patent Citations (6)
Title |
---|
DATABASE PHAR STN; 2003, "Rimonabant", XP002423263 * |
DOGGRELL SHEILA: "Pharmacology down under in 2005--focus on targets.", DRUG NEWS & PERSPECTIVES MAY 2006, vol. 19, no. 4, May 2006 (2006-05-01), pages 233 - 241, XP001536677, ISSN: 0214-0934 * |
HARKAWAY R C ET AL: "Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia.", PROSTATE CANCER AND PROSTATIC DISEASES 2006, vol. 9, no. 3, 6 June 2006 (2006-06-06), pages 204 - 214, XP002423261, ISSN: 1365-7852 * |
NITHIPATIKOM K ET AL: "A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 332, no. 4, 15 July 2005 (2005-07-15), pages 1028 - 1033, XP004929450, ISSN: 0006-291X * |
SANCHEZ M G ET AL: "Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 555, no. 3, 18 December 2003 (2003-12-18), pages 561 - 566, XP004481050, ISSN: 0014-5793 * |
SARFARAZ SAMI ET AL: "Cannabinoid receptor as a novel target for the treatment of prostate cancer", CANCER RESEARCH, vol. 65, no. 5, 1 March 2005 (2005-03-01), pages 1635 - 1641, XP002423260, ISSN: 0008-5472 * |
Also Published As
Publication number | Publication date |
---|---|
JP2009539814A (ja) | 2009-11-19 |
BRPI0711739A2 (pt) | 2011-12-06 |
UY30400A1 (es) | 2008-01-31 |
MX2008015474A (es) | 2009-01-12 |
CN101460169A (zh) | 2009-06-17 |
EA200870507A1 (ru) | 2009-06-30 |
IL195079A0 (en) | 2009-08-03 |
AR061236A1 (es) | 2008-08-13 |
EP2037920A1 (fr) | 2009-03-25 |
TW200812583A (en) | 2008-03-16 |
NO20084293L (no) | 2008-12-22 |
US20090124643A1 (en) | 2009-05-14 |
CA2648645A1 (fr) | 2007-12-13 |
CL2007001632A1 (es) | 2008-01-18 |
MA30850B1 (fr) | 2009-11-02 |
KR20090016576A (ko) | 2009-02-16 |
FR2902008A1 (fr) | 2007-12-14 |
AU2007255265A1 (en) | 2007-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1328269B2 (fr) | Association d'un antagoniste du recepteur cb1 et de la sibutramine pour le traitement de l'obesite | |
EP0969835B1 (fr) | Utilisation d' antagonistes des recepteurs aux cannabinoides centraux pour reguler l'appetence | |
EP1272174A1 (fr) | Produit de combinaison comprenant un anti-androgene non steroide et un inhibiteur de tyrosine kinase egfr | |
HUT60139A (en) | Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen | |
EP1257275A2 (fr) | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac | |
RU2480207C2 (ru) | Способ лечения хронического абактериального простатита селективными модуляторами рецепторов эстрогена или ингибиторами ароматазы | |
SG186333A1 (en) | Methods of treating or preventing estrogen-related diseases | |
WO2003082256A2 (fr) | Traitement des dysfonctionnements sexuels a l'aide d'un antagoniste des recepteurs aux cannabinoides cb1 | |
EP2037920A1 (fr) | Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie benigne de la prostate | |
EP1680117A2 (fr) | Utilisation d'un derive du pyrazole pour la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l'obesite | |
US20070129423A1 (en) | Method for treating pain | |
EP1863489A1 (fr) | Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoides et un agent antipsychotique | |
US20070259945A1 (en) | Method for treating pain | |
Tunçtan et al. | Effects of econazole on receptor-operated and depolarization-induced contractions in rat isolated aorta | |
FR2882263A1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales | |
FR2758460A1 (fr) | Utilisation des agonistes des recepteurs beta-3 adrenergiques pour la preparation de medicaments cicatrisants | |
FR2641971A1 (fr) | Composition pharmaceutique antihypertensive associant le benazepril et un diuretique thiazidique | |
CN115969860A (zh) | 一种药物组合物及其用途 | |
FR2861301A1 (fr) | Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. | |
KR101742023B1 (ko) | 보르테조밉을 유효성분으로 함유하는 담석증의 예방 또는 치료용 약학적 조성물 | |
FR2882261A1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 | |
FR2882262A1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales | |
WO2003013605A1 (fr) | Remedes pour maladies prostatiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780020978.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07788825 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2008000586 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2648645 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 572576 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007255265 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007788825 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4821/KOLNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009513726 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2007255265 Country of ref document: AU Date of ref document: 20070601 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2008/015474 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008502691 Country of ref document: PH Ref document number: 08129605 Country of ref document: CO Ref document number: 1020087029775 Country of ref document: KR Ref document number: 200870507 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: PI0711739 Country of ref document: BR Kind code of ref document: A2 Effective date: 20081128 |